Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Nat Med
; 25(3): 477-486, 2019 03.
Article
in En
| MEDLINE
| ID: mdl-30742122
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Glioblastoma
/
Tumor Microenvironment
/
Antibodies, Monoclonal, Humanized
/
Programmed Cell Death 1 Receptor
/
Antineoplastic Agents, Immunological
/
Neoplasm Recurrence, Local
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Nat Med
Journal subject:
BIOLOGIA MOLECULAR
/
MEDICINA
Year:
2019
Type:
Article
Affiliation country:
United States